etavopivat B 10041, etavopivat B 10042
4202-HEM-202
Phase 2 small_molecule active
Quick answer
etavopivat B 10041, etavopivat B 10042 for Sickle Cell Disease is a Phase 2 program (small_molecule) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novo Nordisk A/S
- Indication
- Sickle Cell Disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active